Internationally renowned ophthalmologist and
investment leader joins to support advancement of disruptive
ophthalmic treatments
SAN
CARLOS, Calif., May 3, 2024
/PRNewswire/ -- RevOpsis Therapeutics, a next-generation
biopharmaceutical company spearheading innovation in ophthalmic
therapies, announced today the appointment of Dr. Emmett Cunningham to its Strategic Advisory
Board (SAB) and as a private investor. Dr. Cunningham, a
distinguished figure in the ophthalmic and investment communities,
brings more than twenty years of experience as a full-time
entrepreneur and investor to his new role with RevOpsis.
"I am honored to join RevOpsis as an early
investor and Strategic Advisory Board member." said Dr.
Emmett Cunningham.
Dr. Cunningham is currently Senior Partner at HealthQuest
Capital Management. Prior, he most recently served as a Senior
Managing Director at Blackstone Life Sciences group (BXLS) of
Blackstone, Inc. (BX), through the acquisition of Clarus Ventures
in 2018, where he was a member of the full-time investment team
since Clarus' inception in 2006.
"I am honored to join RevOpsis as an early investor and
Strategic Advisory Board member. My experience is well aligned to
contribute to the RevOpsis mission of revolutionizing ophthalmic
therapies," said Dr. Emmett
Cunningham. "I am impressed by the company's dedication to
innovation and commitment to improving patient care. I look forward
to collaborating with the team to drive their pipeline of
transformative treatments forward."
With a career spanning notable roles at leading investment
firms, Dr. Cunningham's expertise in guiding successful investments
in biotechnology companies is unparalleled. His track record
includes significant contributions to the development and FDA
approval of ten therapeutics, with an additional therapeutic
pending FDA submission.
His visionary leadership and strategic insights have played a
pivotal role in shaping the landscape of ophthalmic therapies,
driving innovation, and fostering growth within the industry. Dr.
Cunningham's prestigious career includes several prominent board
memberships with various noteworthy biopharmaceutical companies
including several ophthalmology focused companies such as Annexon
Biosciences, GrayBug Vision, Nacuity Pharmaceuticals, and Eyconis,
where he is co-founder and executive chair.
"We are excited to welcome Dr. Emmett
Cunningham to our Strategic Advisory Board," said RevOpsis
interim CEO Dr. Ram Bhandari. "Dr. Cunningham's wealth of
experience and deep understanding of the ophthalmic and investment
landscapes make him an invaluable asset to the RevOpsis SAB. Dr.
Cunningham's guidance will be instrumental as we continue to
advance our proprietary Rev-Mod Platform and develop novel
treatments for chronic multifactorial diseases, including our
current lead candidate RO-104."
In addition to his remarkable achievements in the investment
sector, Dr. Cunningham is widely recognized as an internationally
renowned specialist in infectious and inflammatory eye diseases. He
has authored over 400 publications and made significant
contributions to advancing the understanding and treatment of
vision-related disorders.
About RO-104
Leveraging the proprietary Rev-Mod
platform, RO-104 is RevOpsis' current lead candidate. Engineered as
a first-in-class fully human modular tri-specific
biologic designed to address all three clinically validated
dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) implicated in
retinal vascular disease progression, including neovascular
age-related macular degeneration (nAMD). RO-104 represents a
significant innovative advancement in the treatment landscape for
retinal vascular diseases. Backed by a significant body of
preclinical evidence demonstrating intended efficacy and safety in
established animal models, RO-104 heralds a transformative approach
positioned to redefine the current standard of care for patients
with nAMD.
About Rev-Mod Platform
The proprietary Rev-Mod
Platform employs a modular 'plug-and-play' approach to streamline
and expedite the efficient discovery and development of
multispecific biologics targeting a wide spectrum of chronic,
prevalent, large diseases, that are the leading causes of death and
disability worldwide. Our proprietary platform boasts a vast
library of nearly 30 billion fully human antibody components in a
structured phage display system, facilitating rapid identification
and assembly of multispecific product candidates. With seamless
compatibility, the Rev-Mod platform enables swift and efficient
design of multispecific biologics to address unmet needs in major
therapeutic areas including ophthalmology, oncology, and
immune-mediated diseases.
About RevOpsis Therapeutics
Founded in 2018, RevOpsis
Therapeutics is a privately held, next-generation biopharmaceutical
company spearheading innovation in ophthalmic therapies. Guided by
a team of leading physicians, scientists, and business leaders, we
are dedicated to leveraging our proprietary Rev-Mod Platform to
develop and commercialize groundbreaking treatments for chronic
multifactorial diseases. With a steadfast commitment to responsibly
advancing patient care, we aim to usher in a new era of
improved disease management and extended disease remission. For
more information, please visit www.revopsis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/revopsis-welcomes-dr-emmett-cunningham-to-strategic-advisory-board-302135444.html
SOURCE RevOpsis